60 Degrees Pharmaceuticals (NASDAQ:SXTP) Given “Sell (E+)” Rating at Weiss Ratings

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings in a research report issued to clients and investors on Saturday,Weiss Ratings reports.

SXTP has been the subject of several other research reports. Wall Street Zen downgraded shares of 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, June 14th. Ascendiant Capital Markets reduced their target price on 60 Degrees Pharmaceuticals from $7.00 to $3.00 and set a “buy” rating for the company in a report on Wednesday, September 3rd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, 60 Degrees Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $3.00.

60 Degrees Pharmaceuticals Trading Down 2.1%

Shares of NASDAQ:SXTP opened at $1.37 on Friday. The stock has a fifty day simple moving average of $1.47 and a two-hundred day simple moving average of $2.04. 60 Degrees Pharmaceuticals has a 12-month low of $1.22 and a 12-month high of $12.45. The stock has a market capitalization of $5.62 million, a price-to-earnings ratio of -0.03 and a beta of 2.72.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($1.24) by ($0.01). The firm had revenue of $0.31 million during the quarter, compared to analysts’ expectations of $0.32 million. As a group, equities research analysts predict that 60 Degrees Pharmaceuticals will post -5.09 EPS for the current year.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.